NASDAQ · Stocky rates: Avoid

IBRX

$7.25 ▲ +4.32% as of 5 Aug, 20:00
21
/ 100
Avoid

What Stocky thinks

Avoid. IBRX scores just 14/100 on Value Compounder metrics, indicating weak earnings growth and returns on capital—the foundation of durable shareholder value. While Leadership Alignment (61/100) suggests moderate founder-CEO stewardship, deteriorating fundamentals and lack of competitive moat create a vulnerable risk/reward profile unsuitable for patient capital.

Compounder Score
14/100
Business quality — profitability, growth, capital efficiency.
Leadership Alignment
61/100
Founder-led, insider ownership, capital allocation history.
Vulnerability
0/100
Downside resilience — customer concentration, supply chain, refinancing risk.
Value Score
14/100
Valuation vs peers and history — is this a good price to pay?

What Stocky gives investors that other tools don't

Every stock is scored across six proprietary dimensions built for retail investors who want Buffett-quality analysis without a Bloomberg subscription. Here's the actual snapshot for IBRX:

21
VERDICT

Stocky Verdict — one score, everything

Quality + moat + leadership + valuation + sentiment fused into a single 0–100 number. When you see 21/100, you know instantly whether to dig deeper or skip.

Rated
MOAT

Moat Score — is there a real edge?

Pricing power, switching costs, network effects, and 10-year ROIC data. Same framework Morningstar charges for — free inside Stocky.

61
LEADER

Leadership Alignment — is management on your side?

Founder tenure, insider ownership, CEO pay reasonableness, long-term value creation. Six factors, one score — turns "trust the CEO" into evidence.

0
RISK

Vulnerability Profile — what could break?

Customer concentration, supply chain, refinancing walls, regulatory exposure. Stocky maps knowable fragilities so you're never blindsided.

Elite
TRACK

Track Record — does the system work?

Every score backtested against real S&P 500 returns. See how "Elite" (90+ Verdict) picks have performed vs the index — no black boxes.

24/7
ALERTS

Alerts + Portfolio insights

Analyst target shifts, insider buys, big moves — plus a monthly Portfolio Health Report telling you what's actually driving your returns.

IBRX (IBRX) — frequently asked

Is IBRX (IBRX) a good investment right now?

Stocky rates IBRX (IBRX) at 21/100 — an Avoid — fundamentals or risks are too weak. The score fuses business quality, moat width, leadership alignment, valuation and analyst signal into a single number. Avoid. IBRX scores just 14/100 on Value Compounder metrics, indicating weak earnings growth and returns on capital—the foundation of durable shareholder value. While Leadership Alignment (61/100) suggests moderate founder-CEO stewardship, d

What is IBRX's Stocky Verdict?

IBRX's current Stocky Verdict is 21/100, placing it in the "Avoid" band. This composite combines a 14/100 Compounder score, 61/100 Leadership, Moat rating, and analyst signal.

Does IBRX have a competitive moat?

Stocky hasn't finalised a Moat Score for IBRX yet — the analysis draws from ROIC trends, pricing power evidence, and competitive-position filings.

Is IBRX's leadership aligned with shareholders?

IBRX scores 61/100 on Leadership Alignment. Higher = more founder involvement, higher insider ownership, sensible pay, and evidence of long-term capital allocation discipline.

What are the biggest risks to IBRX?

IBRX's Vulnerability Profile scores 0/100 (higher = more resilient). The profile flags customer concentration, supply chain, refinancing walls and regulatory risks specific to IBRX.

This is just the surface. See the whole picture on IBRX.

Sign up free and unlock the full analysis on IBRX — the same tools professional analysts use, personalised to your portfolio:

  • Every analyst covering IBRX — full list with star ratings, price targets, historical hit-rate. Not just the top 3 you see above.
  • Full Vulnerability Profile — customer concentration, refinancing walls, stress-test scenarios (-20% revenue, +200bp rates) modelled specifically for IBRX.
  • Bull & bear thesis — the AI-written counter-argument every retail investor forgets to read.
  • Portfolio fit check — how IBRX changes your sector concentration, correlation and Verdict-weighted quality.
  • Ask Stocky AI — "What are the biggest 3-year risks to IBRX?" · "Is IBRX overvalued vs its 5-year median?" · unlimited follow-ups on your portfolio.
  • Live alerts — analyst target changes, insider buys, big moves — the day they happen.
Start free · 14 days Plus, no card →

Free forever tier includes 5 Verdict lookups a day. Plus €19/mo unlocks everything above. Cancel any time.

STOCKY VERDICT
21
/ 100 · Avoid

Or jump straight to the interactive dashboard for IBRX in the app.